Altering the intestinal microbiome in cystic fibrosis
AssigneesTrastees of Dartmouth College, Dartmouth-Hitchcock Clime
InventorsGeorge A. O'Toole, Juliette C. Madan
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a method of altering intestinal microbiome in a patient having cystic fibrosis comprising administering at least one of Bifidobacterium and/or Bacteroides to a patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome.
Claims20
A method of altering the intestinal microbiome in a patient diagnosed with cystic fibrosis, the method comprising:
- (a) administering at least one of Bifidobacterium and/or Bacteroides to the patient and allowing the Bifidobacterium and/or Bacteroides to alter the intestinal microbiome;
- or
- (b) administering at least one of Streptococcus and/or Ruminococcus to the patient and allowing the Streptococcus and/or Ruminococcus to alter the intestinal microbiome.
A method of preventing, delaying the onset, reducing the severity, and/or reducing the duration of an infection by a pathogen, or an exacerbation thereof, in a patient in need thereof, the method comprising:
- administering to the patient at least one of Bifidobacterium and/or Bacteroides to the patient, wherein prior to said administration a sample from the patient has been tested to determine a level of Bifidobacterium and/or Bacteroides.
A method of treating cystic fibrosis in a patient in need thereof, the method comprising:
- administering an effective amount of cystic fibrosis therapy to the subject thereby treating cystic fibrosis, wherein the cystic fibrosis therapy is selected from the group consisting of:
- i. at least one pancreatic enzyme replacement product;
- ii. at least one probiotic;
- iii. at least one prebiotic;
- iv. at least one antibiotic;
- v. at least one anti-inflammatory medication;
- vi. at least one mucus-thinning drug;
- vii. at least one cystic fibrosis transmembrane conductance regulator (CFTR) function-improving medication;
- viii. at least one bronchodilator or inhaled medication;
- and
- ix. a combination thereof;
- wherein, prior to said administration, a fecal sample from the patient has been tested to determine whether the patient has a decreased level of Bifidobacterium, Bacteroides, Faecalibacterium, Clostridiales, Roseburia, Ruminococcaceae, Eubacterium, Streptococcus, and/or Ruminococcus relative to a healthy control population.
Dependencies are inferred from the claim text.